Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 3Phase 2 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Pancreatic Neoplasms 97Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Neoplasm Metastasis 23Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Sarcoma 15Lung Neoplasms 14Biliary Tract Neoplasms 13Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Lymphoma 10Cholangiocarcinoma 10Recurrence 9Hodgkin Disease 8Carcinoma, Transitional Cell 8Adenocarcinoma 8Lymphoma, Non-Hodgkin 7Triple Negative Breast Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Lymphoma, Follicular 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Gastrointestinal Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4

Interventions

Injections 13toripalimab 12pembrolizumab 4atezolizumab 4Gemcitabine 4Carboplatin 4Cisplatin 3trastuzumab deruxtecan 2tislelizumab 2spartalizumab 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Albumin-Bound Paclitaxel 2talazoparib 1sintilimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1mirdametinib 1enfortumab vedotin 1conteltinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Letrozole 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumor × Gemcitabine × Clear all
NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed
276 enrolled 33 charts
Other solid neoplasm

Advanced Solid Tumor

NCT06139211 2024-12-20

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04934514 2024-02-20

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

SUNHO(China)BioPharmaceutical CO., Ltd.

Phase 1/2 Unknown
97 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05525247 2023-09-21

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Selecxine

Phase 1/2 Recruiting
420 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡